Brian Elsbernd Sells 25,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Brian Elsbernd sold 25,000 shares of the business’s stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $16.44, for a total value of $411,000.00. Following the sale, the insider now owns 124,433 shares in the company, valued at approximately $2,045,678.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Catalyst Pharmaceuticals Stock Down 2.0 %

Shares of CPRX opened at $15.94 on Friday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $11.09 and a 52 week high of $18.22. The stock has a market cap of $1.88 billion, a P/E ratio of 26.13, a P/E/G ratio of 1.14 and a beta of 0.92. The business’s 50 day moving average price is $14.99 and its 200-day moving average price is $14.18.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.04. Catalyst Pharmaceuticals had a net margin of 17.93% and a return on equity of 26.56%. The business had revenue of $110.57 million during the quarter, compared to analyst estimates of $105.78 million. On average, equities analysts anticipate that Catalyst Pharmaceuticals, Inc. will post 1.57 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on CPRX. StockNews.com upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $34.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, March 22nd. Bank of America began coverage on Catalyst Pharmaceuticals in a research note on Thursday, March 7th. They issued a “buy” rating and a $23.00 price objective for the company. Oppenheimer reaffirmed an “outperform” rating and set a $29.00 price target on shares of Catalyst Pharmaceuticals in a research report on Wednesday. Finally, Citigroup assumed coverage on Catalyst Pharmaceuticals in a report on Thursday, March 14th. They set a “buy” rating and a $27.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $26.43.

Institutional Trading of Catalyst Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. American Century Companies Inc. increased its position in shares of Catalyst Pharmaceuticals by 20.6% during the third quarter. American Century Companies Inc. now owns 899,478 shares of the biopharmaceutical company’s stock worth $10,515,000 after acquiring an additional 153,697 shares during the period. Illinois Municipal Retirement Fund purchased a new position in shares of Catalyst Pharmaceuticals in the third quarter worth $711,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 6.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 921,327 shares of the biopharmaceutical company’s stock worth $10,770,000 after purchasing an additional 58,018 shares during the last quarter. Swiss National Bank raised its holdings in shares of Catalyst Pharmaceuticals by 1.8% during the third quarter. Swiss National Bank now owns 222,500 shares of the biopharmaceutical company’s stock worth $2,601,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Jackson Creek Investment Advisors LLC acquired a new position in shares of Catalyst Pharmaceuticals in the third quarter worth about $797,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.